Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 2.93
- Piotroski Score 6.00
- Grade Neutral
- Symbol (BIIB)
- Company Biogen Inc.
- Price $173.90
- Changes Percentage (-0.29%)
- Change -$0.5
- Day Low $172.95
- Day High $176.95
- Year High $268.30
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 01/30/2025
- Fiscal Year End N/A
- Average Stock Price Target $275.00
- High Stock Price Target $400.00
- Low Stock Price Target $202.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $8.00
- Trailing P/E Ratio 28.18
- Forward P/E Ratio 28.18
- P/E Growth 28.18
- Net Income $1.16 B
Income Statement
Quarterly
Annual
Latest News of BIIB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Biogen Inc. (BIIB): An Oversold Large Cap Stock To Buy Now
A list of oversold large cap stocks includes Biogen Inc. The recent Fed rate cuts and market performance suggest optimism. Noah Blackstein's positive outlook on equity markets emphasizes the need for ...
By Yahoo! Finance | 2 weeks ago -
Is Biogen Inc. (BIIB) the Best QQQ Stock to Buy According to Analysts?
An analysis of the best QQQ stocks to buy includes Biogen Inc. The Fed's rate cuts impact the market positively, with strong economic growth. Quality stocks are essential in the current uncertain clim...
By Yahoo! Finance | 2 weeks ago -
Biogen Inc. (BIIB): Worst Performing NASDAQ Stock in 2024
The article discusses the poor performance of Biogen Inc. (NASDAQ:BIIB) in 2024 compared to other NASDAQ stocks. Factors impacting stock market momentum include AI, earnings, interest rates, and geopo...
By Yahoo! Finance | 2 weeks ago
